Results 111 to 120 of about 42,414 (275)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation

BMC Infectious Diseases, 2016
BackgroundThe endgame for polio eradication involves coordinated global cessation of oral poliovirus vaccine (OPV) with cessation of serotype 2 OPV (OPV2 cessation) implemented in late April and early May 2016 and cessation of serotypes 1 and 3 OPV ...
R. D. Duintjer Tebbens, L. Hampton, K. Thompson   +2 more
semanticscholar   +1 more source

Oncolytic Viruses Reshape PD‐1/PD‐L1 Signaling: Mechanisms and Clinical Synergy With Immune Checkpoint Blockade

Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.
Oncolytic viruses (OVs) are naturally occurring or genetically engineered viruses that selectively target and destroy cancer cells. They act through multiple mechanisms, including direct tumor cell lysis, stimulation of immune‐mediated cytotoxicity, and modulation of the tumor microenvironment (TME).
Seyedeh Nasim Mirbahari, Mehdi Bakhtiyaridovvombaygi, Hamid Mahdizadeh, Amirhossein Izadpanah, Elham Roshandel, Mehdi Totonchi, Hongda Liu   +6 more
wiley   +1 more source

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use

BMC Infectious Diseases, 2016
BackgroundThe endgame for polio eradication includes coordinated global cessation of oral poliovirus vaccine (OPV), starting with the cessation of vaccine containing OPV serotype 2 (OPV2) by switching all trivalent OPV (tOPV) to bivalent OPV (bOPV).
R. D. Duintjer Tebbens, L. Hampton, K. Thompson   +2 more
semanticscholar   +1 more source

Migratory Wave due to Conflicts: Risk of Increased Infection From Zoonotic Diseases

Transboundary and Emerging Diseases, Volume 2025, Issue 1, 2025.
Wars have devastating effects on all the components of the One Health approach: humans, animals, and ecosystems. Wars and the resulting migratory waves massively disrupt normal animal health services and surveillance. Among other consequences, they adversely impact the early detection, prevention, and control of animal diseases.
Sina Salajegheh Tazerji, Phelipe Magalhães Duarte, Rasha Gharieb, Lukasz Szarpak, Michal Pruc, Md. Tanvir Rahman, Alfonso J. Rodriguez-Morales, Muhammad Furqan Ilyas, Maria de Nazaré Santos Ferreira, Yashpal Singh Malik, Roozbeh Kalantari, Ava Shahrokhabadi, Niloofar Jafari, Fatemeh Shahabinejad, Yasaman Maleki, Sina Montajeb, Roya Mehrpouya, Hadis Ahmadi, Bita Vazir, Farrokhreza Kabir, Abdul Rehman, Zahra Elmi, Pouneh Hajipour, Hesham R. El-Seedi, Wolfgang Eisenreich, Awad A. Shehata, Chunfu Zheng   +26 more
wiley   +1 more source

Comparative study of antibody levels developed by vaccination against polio virus in population after vaccine type alteration [PDF]

, 2015
During clinical trials, samples from Hungarian patients of different age groups were tested for antibodies against all 3 serotypes of poliovirus, a member of Picornaviridae family.
Farkas, Ágnes, Magyar, Nóra, Szomor, Katalin, Takács, Mária   +3 more
core   +1 more source

Assessing the Risk of Vaccine-derived Outbreaks After Reintroduction of Oral Poliovirus Vaccine in Postcessation Settings

Clinical Infectious Diseases, 2018
Background The Polio Eradication and Endgame Strategic Plan 2013–2018 calls for the gradual withdrawal of oral poliovirus vaccine (OPV) from routine immunization.
Rui Fu, J. Altamirano, C. Sarnquist, Y. Maldonado, J. Andrews   +4 more
semanticscholar   +1 more source

Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue

MedComm, Volume 5, Issue 12, December 2024.
Breakthroughs have been made in the prevention and treatment of respiratory syncytial virus (RSV). Three RSV vaccines, two RSV monoclonal antibodies, and one RSV therapeutic agent have been approved for marketing, and multiple other products are in the clinical study phase.
Qianqian Li, Huan Li, Zhihua Li, Youchun Wang   +3 more
wiley   +1 more source

Hospital discharges-based search of acute flaccid paralysis cases 2007-2016 in Italy and comparison with the National Surveillance System for monitoring the risk of polio reintroduction [PDF]

, 2019
Background: Acute flaccid paralysis (AFP) surveillance has been adopted globally as a key strategy for monitoring the progress of the polio eradication initiative.
Affanni P., Amato C., Ansaldi F., Arghittu A., Bellino S., Binda S., Bonaccorsi G., Brusaferro S., Buttinelli G., Camilloni B., Capannolo B., Carraro V., Castiglia P., D'errico M.M., De Grazia S., De Stefano C., Fiore S., Foca A., Fontana S., Germinario C., Giammanco G., Grasso G.M., Larocca A., Lombardi D., Lorini C., Mancini C., Napoletano G., Pellegrinelli L., Pennino F., Russo F., Spertini S., Stefanelli P., Triassi M., Vairo F., Veronesi L., Zanella F.   +35 more
core   +5 more sources

Virologic Monitoring of Poliovirus Type 2 after Oral Poliovirus Vaccine Type 2 Withdrawal in April 2016 — Worldwide, 2016–2017

MMWR. Morbidity and mortality weekly report, 2017
The Global Polio Eradication Initiative (GPEI) has made substantial progress since its launch in 1988; only 37 wild poliovirus type 1 (WPV1) cases were detected in 2016, the lowest annual count ever.
O. Diop, H. Asghar, E. Gavrilin, Nicksy Gumede Moeletsi, G. Benito, F. Paladin, S. Pattamadilok, Yan Zhang, A. Goel, A. Quddus   +9 more
semanticscholar   +1 more source

Emerging Therapeutics in the Fight Against EV‐D68: A Review of Current Strategies

Influenza and Other Respiratory Viruses, Volume 18, Issue 12, December 2024.
ABSTRACT Enterovirus‐D68 (EV‐D68) was first identified in 1962 in pediatric patients with acute respiratory conditions in California, USA (US). From the 1970s to 2005, EV‐D68 was underestimated due to limited data and serotyping methods. In 2014, the United States experienced outbreaks of acute flaccid myelitis (AFM) in children EV‐D68 positive.
Nida Kalam, Vinod R. M. T. Balasubramaniam   +1 more
wiley   +1 more source